Lusaris’s lead program is LSR-1019, a proprietary sublingual formulation of 5-MeO-DMT designed to be fast-acting and rapidly clearing for patients with treatment-resistant depression (TRD) and other severe neuropsychiatric conditions. The sublingual tablet dissolves under the tongue and is absorbed without water, aiming to avoid gut and liver metabolism and provide more consistent exposure versus oral dosing. Lusaris plans to develop LSR-1019 for TRD and additional severe neuropsychiatric disorders, and expects Phase 1 clinical studies to initiate imminently with topline data available mid‑year 2023. The company has a strategic collaboration with Catalent and an exclusive worldwide license to Catalent’s Zydis® fast-dissolving tablet technology for the 5-MeO-DMT program. In addition to LSR-1019, Lusaris is building a pipeline of novel serotonergic neuroplastogens for conditions including migraine and cluster headache. The company launched with institutional investor backing and an experienced leadership team to advance its clinical programs.

Total raised

$60M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2022